- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03009201
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas
Study Overview
Status
Conditions
- Stage III Soft Tissue Sarcoma AJCC v7
- Stage IV Soft Tissue Sarcoma AJCC v7
- Locally Advanced Leiomyosarcoma
- Unresectable Leiomyosarcoma
- Myxofibrosarcoma
- Metastatic Malignant Peripheral Nerve Sheath Tumor
- Metastatic Synovial Sarcoma
- Metastatic Undifferentiated Pleomorphic Sarcoma
- Unresectable Soft Tissue Sarcoma
- Advanced Soft Tissue Sarcoma
- Metastatic Soft Tissue Sarcoma
- Pleomorphic Rhabdomyosarcoma
- Metastatic Liposarcoma
- Unresectable Synovial Sarcoma
- Locally Advanced Angiosarcoma
- Locally Advanced Liposarcoma
- Locally Advanced Malignant Peripheral Nerve Sheath Tumor
- Locally Advanced Myxofibrosarcoma
- Locally Advanced Undifferentiated Pleomorphic Sarcoma
- Metastatic Angiosarcoma
- Metastatic Epithelioid Sarcoma
- Metastatic Fibrosarcoma
- Metastatic Myxofibrosarcoma
- Undifferentiated (Embryonal) Sarcoma
- Unresectable Liposarcoma
- Unresectable Malignant Peripheral Nerve Sheath Tumor
- Unresectable Undifferentiated Pleomorphic Sarcoma
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the recommended phase 2 dose (RP2D) of ribociclib in combination with doxorubicin in subjects with advanced soft tissue sarcomas.
SECONDARY OBJECTIVES:
I. To assess preliminary anti-tumor activity of ribociclib in combination with doxorubicin in subjects with advanced soft tissue sarcomas.
II. To characterize the safety and tolerability of ribociclib in combination with doxorubicin.
OUTLINE: This is a dose-escalation study of ribociclib.
Patients receive ribociclib orally (PO) daily on days 1-7, and doxorubicin hydrochloride intravenously (IV) on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Patients without disease progression after 6 cycles receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up within 30 days and then every 12 weeks for 12 months.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- OHSU Knight Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Pathologically confirmed diagnosis of intermediate or high-grade soft tissue sarcoma for which single-agent doxorubicin is appropriate therapy, including but not limited to:
- Synovial sarcoma
- Fibrosarcoma
- Undifferentiated sarcoma
- Liposarcoma
- Leiomyosarcoma
- Angiosarcoma
- Malignant peripheral nerve sheath tumor
- Pleomorphic rhabdomyosarcoma
- Myxofibrosarcoma
- Epithelioid sarcoma
- Undifferentiated pleomorphic sarcoma
- Locally advanced unresectable or metastatic disease with no standard curative therapy available
- Archival tumor tissue retinoblastoma-associated protein (pRb) positive by immunohistochemistry (IHC)
- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- All races and ethnic groups will be included; for subjects between the ages of 12-18 years only, body surface area (BSA) must be >= 1.28 m^2
- Ejection fraction of >= 50% by echocardiogram or multi-gated acquisition (MUGA) scan
- Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening and within 14 days prior to planned first dose of ribociclib
- Willing to use adequate contraception throughout the study and for 3 weeks after study drug discontinuation
Meets the following standard 12-lead electrocardiography (ECG) parameters at screening (defined as the mean of the triplicate ECGs; ECGs done in triplicate do not have a defined interval between assessments):
- Corrected QT using Fridericia's correction formula (QTcF) interval at screening < 450 msec for males and < 470 msec for females (using Fridericia's correction)
- Resting heart rate =< 100 beats per minute (bpm)
- Absolute neutrophil count (ANC) >= 1.5 K/cu mm
- Platelets (no transfusion within prior 7 days) >= 100 K/cu mm
- Hemoglobin (no transfusion within prior 7 days) >= 9.0 g/dL
- Total bilirubin < institutional upper limit of normal (ULN), except for subjects with documented Gilbert's syndrome, for which =< 3.0 x ULN or direct bilirubin =< 1.5 x ULN
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT) in the absence of liver metastases: =< 2.5 x ULN; if the subject has liver metastases: < 5 x ULN
- Serum creatinine < 1.7 mg/dL
- Potassium within institutional normal limit (WNL)
- Corrected calcium WNL
- Magnesium WNL
International normalized ratio (INR) =< 1.5
- Use of rivaroxaban, apixaban, edoxaban or warfarin is an exclusion criteria; therapy with heparin, low molecular weight heparin (LMWH), dabigatran or fondaparinux is allowed
- All prior treatment-related toxicities resolved to =< grade 1 or are determined to be clinically stable by the investigator
Has completed prior therapies according to the criteria below:
- Cytotoxic chemotherapy - at least 21 days since last dose prior to first dose of ribociclib
- Small molecule inhibitors - at least 14 days since last dose prior to first dose of ribociclib
- Monoclonal antibodies - at least 3 half-lives since last dose prior to first dose of ribociclib; exception: denosumab for bony metastases is allowable
- Immunotherapy (e.g. tumor vaccines) - at least 42 days since last dose prior to first dose of ribociclib
- Radiation - at least 14 days since last dose prior to first dose of ribociclib
- Able to swallow capsules
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Life expectancy > 3 months
- Ability to understand and the willingness to sign a written informed consent document; subject has signed the informed consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements
Exclusion Criteria:
- Subjects with low grade tumors (histologic grade 1/3)
Histologic diagnosis for which single-agent doxorubicin is NOT appropriate therapy, including but not limited to:
- Alveolar or embryonal rhabdomyosarcoma
- Ewings sarcoma or primitive neuroectodermal tumor (PNET)
- Osteosarcoma
- Gastrointestinal stromal tumor (GIST)
- Prior systemic therapy with an anthracycline for any indication
- Known hypersensitivity to any of the excipients of ribociclib or doxorubicin (including to peanut and soy)
Currently receiving any of the following that cannot be discontinued at least 7 days prior to starting study drug:
- Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges
- Medications with a narrow therapeutic window that are predominantly metabolized through CYP3A4/5
- Herbal supplements, such as St. John's wort; the use of marijuana or its derivatives is allowed in States with statutes permitting the use of recreational or medical marijuana
Uncontrolled intercurrent medical condition including, but not limited to:
- Uncontrolled infection
- Symptomatic congestive heart failure (New York Heart Association [NYHA] class III-IV)
- Acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening
- Uncontrolled cardiac arrhythmia or arrhythmia requiring medication other than beta blocker
- Psychiatric illness/social situations that would limit compliance with study requirements
- Any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, etc.)
Concurrent malignancy or malignancy within 3 years prior to starting study drug, except:
- Malignancies that have completed therapy and are considered by their physician to be at less than 30% risk of relapse, or
- Malignancies not requiring treatment (e.g., RAI stage 0 chronic lymphocytic leukemia [CLL])
Central nervous system (CNS) involvement unless they meet ALL of the following criteria:
- At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment
- Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea/vomiting/diarrhea, malabsorption syndrome, or major small bowel resection)
- Known history of human immunodeficiency virus (HIV) infection (testing not mandatory); NOTE: HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ribociclib; in addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated
- Systolic blood pressure (SBP) > 160 mmHg or < 90 mmHg at screening; if initial screening SBP is outside of the eligible range, blood pressure may be re-checked after intervention; SBP must be documented as stable and within the eligible range prior to starting study drug
- Currently receiving rivaroxaban, apixaban, endoxaban, warfarin or other warfarin derived anticoagulant; therapy with heparin, low molecular weight heparin (LMWH), dabigatran or fondaparinux is allowed; if transitioning from a prohibited anticoagulant, a minimum washout of 7 days from last dose of the prohibited medication is required prior to ribociclib start
- Participation in a prior investigational interventional study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
- Major surgery within 14 days prior to starting study drug or has not recovered from surgical complications (tumor biopsy is not considered as major surgery)
- History of congenital long QT syndrome or torsades de pointes
- History of non-compliance to medical regimen or inability to grant consent
- Pregnant or nursing (lactating) women; breastfeeding should be discontinued
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (ribociclib, doxorubicin hydrochloride)
Patients receive ribociclib PO daily on days 1-7, and doxorubicin hydrochloride IV on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Correlative studies
Correlative studies
Given IV
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of dose limiting toxicities (DLTs) of adverse events
Time Frame: Up to 21 days
|
Will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03.
All adverse events (AEs) will be tabulated and summarized by major organ category, grade, anticipation, and drug attribution.
Serious adverse events (SAE) specific incidence and exact 95% confidence interval will be provided where appropriate.
|
Up to 21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: From first dose of protocol therapy to time of documented radiographic and/or clinical disease progression or death from any cause, whichever occurs first, assessed up to 12 months
|
The Kaplan-Meier product limit method will be used to estimate PFS of the median PFS and PFS rates at clinically relevant time points will be provided with the 90% confidence interval (CI).
|
From first dose of protocol therapy to time of documented radiographic and/or clinical disease progression or death from any cause, whichever occurs first, assessed up to 12 months
|
Objective response rate (ORR)
Time Frame: Up to 12 months
|
Will be defined as the proportion of patients who achieved a complete response or a partial response.
Will be assessed based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.
The ORR, along with exact two-sided 95% confidence intervals, will be reported for the study.
|
Up to 12 months
|
Incidence of adverse events, SAEs
Time Frame: Up to 12 months
|
Will be assessed by NCI CTCAE v 4.03.
Analyses will be performed for all patients having received at least one dose of study drug.
Serious adverse events, AEs will be summarized using descriptive statistics.
|
Up to 12 months
|
Incidence of dose modifications (interruptions, reductions, intensity) due to adverse events
Time Frame: Up to 12 months
|
Analyses will be performed for all patients having received at least one dose of study drug.
AEs leading to withdrawal/dose interruptions/dose modification will be summarized using descriptive statistics.
|
Up to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lara E Davis, OHSU Knight Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neuromuscular Diseases
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Nervous System Neoplasms
- Neoplasms, Connective Tissue
- Neoplasms, Vascular Tissue
- Neoplasms, Muscle Tissue
- Peripheral Nervous System Neoplasms
- Neoplasms, Adipose Tissue
- Myosarcoma
- Neoplasms, Fibrous Tissue
- Neurofibroma
- Histiocytoma
- Sarcoma
- Leiomyosarcoma
- Nerve Sheath Neoplasms
- Liposarcoma
- Rhabdomyosarcoma
- Hemangiosarcoma
- Neurofibrosarcoma
- Sarcoma, Synovial
- Histiocytoma, Malignant Fibrous
- Fibrosarcoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- STUDY00016070 (Other Identifier: OHSU Knight Cancer Institute)
- NCI-2016-01794 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage III Soft Tissue Sarcoma AJCC v7
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupTerminatedRecurrent Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 | Stage II Adult Soft Tissue Sarcoma AJCC v7 | Stage III Adult Soft Tissue Sarcoma AJCC v7United States
-
OHSU Knight Cancer InstituteBayer; Oregon Health and Science UniversityCompletedPleomorphic Rhabdomyosarcoma | Stage III Adult Soft Tissue Sarcoma AJCC v7 | Stage IV Adult Soft Tissue Sarcoma AJCC v7 | Stage IIB Adult Soft Tissue Sarcoma AJCC v7United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Janssen PharmaceuticalsWithdrawnMyxoid Liposarcoma | Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Round Cell Liposarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingSarcoma | Rhabdomyosarcoma | Adult Rhabdomyosarcoma | Childhood Alveolar Rhabdomyosarcoma | Childhood Embryonal Rhabdomyosarcoma | Childhood Botryoid-Type Embryonal Rhabdomyosarcoma | Localized Childhood Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 | Stage II Adult Soft Tissue Sarcoma... and other conditionsUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
National Cancer Institute (NCI)CompletedStage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Pleomorphic Liposarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Metastatic Unresectable Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue Sarcoma | Metastatic... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Ewing Sarcoma | Recurrent Osteosarcoma | Stage III Osteosarcoma AJCC v7 | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma | Metastatic Ewing Sarcoma | Unresectable Ewing Sarcoma | Unresectable OsteosarcomaFrance
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChordoma | Rhabdomyosarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Untreated Childhood Rhabdomyosarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 and other conditionsUnited States, Netherlands, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
National Cancer Institute (NCI)Active, not recruitingSoft Tissue Sarcoma | Leiomyosarcoma | Liposarcoma | Undifferentiated Pleomorphic Sarcoma | Soft Tissue Sarcoma of the Trunk and Extremities | Stage I Soft Tissue Sarcoma AJCC v7 | Stage II Soft Tissue Sarcoma AJCC v7 | Sarcoma G2 | Sarcoma G3United States, Canada
-
M.D. Anderson Cancer CenterRecruitingStage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Resectable... and other conditionsUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States